Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A

Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential for significant further milestones View original content:https://www.prnewswire.co.uk/news-releases/rappta-therapeutics-enters-into-a-global-license-agreement-with-springworks-therapeutics-for-a-pre-clinical-first-in-class-molecular-glue-targeting-pp2a-302348216.html

en | boerse | 67938990 |